Pfizer’s Lorbrena scores US priority review
Drug is being reviewed for ALK-positive lung cancer
Read More
Tag: Lorbrena
Pfizer’s new lung cancer drug bags US clearance
Pfizer’s new lung cancer treatment Lorbrena has bagged US approval for previously treated patients with a specific gene mutation and metastatic disease.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
